Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis

Victoria T. Brown; Dana Drzayich Antol; Patrick N. Racsa; Melea A. Ward; Jarushka Naidoo

doi:10.1080/07357907.2021.1913502

Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis

Victoria T. Brown, Dana Drzayich Antol, Patrick N. Racsa, Melea A. Ward, Jarushka Naidoo

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods: irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Results: Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. Conclusion: These data underscore the needs for tailored irAE diagnostic and management pathways.

Original language	English (US)
Pages (from-to)	789-796
Number of pages	8
Journal	Cancer Investigation
Volume	39
Issue number	10
DOIs	https://doi.org/10.1080/07357907.2021.1913502
State	Published - 2021

Keywords

Therapy
cancer in the elderly
treatment

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1080/07357907.2021.1913502

Cite this

@article{a7415af23bdb4bfc97cbed40c32ff751,

title = "Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis",

abstract = "Purpose: We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods: irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Results: Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. Conclusion: These data underscore the needs for tailored irAE diagnostic and management pathways.",

keywords = "Therapy, cancer in the elderly, treatment",

author = "Brown, {Victoria T.} and Antol, {Dana Drzayich} and Racsa, {Patrick N.} and Ward, {Melea A.} and Jarushka Naidoo",

note = "Funding Information: Monica Nicosia, PhD, Nicosia Medical Writer LLC, and Mary Costantino, PhD provided medical editing and writing support, funded by Humana Inc. Publisher Copyright: {\textcopyright} 2021 Taylor & Francis Group, LLC.",

year = "2021",

doi = "10.1080/07357907.2021.1913502",

language = "English (US)",

volume = "39",

pages = "789--796",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors

T2 - Retrospective Claims-Based Analysis

AU - Brown, Victoria T.

AU - Antol, Dana Drzayich

AU - Racsa, Patrick N.

AU - Ward, Melea A.

AU - Naidoo, Jarushka

N1 - Funding Information: Monica Nicosia, PhD, Nicosia Medical Writer LLC, and Mary Costantino, PhD provided medical editing and writing support, funded by Humana Inc. Publisher Copyright: © 2021 Taylor & Francis Group, LLC.

PY - 2021

Y1 - 2021

N2 - Purpose: We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods: irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Results: Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. Conclusion: These data underscore the needs for tailored irAE diagnostic and management pathways.

AB - Purpose: We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods: irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated treatment with anti-PD(L)-1 and received ≥ 1 dose of therapy between 1 September 2014 and 28 February 2018. Results: Treatment was discontinued for 46.6% of patients, and withheld and subsequently restarted for 10.3%. While toxicity profiles did not differ by age, RiskRx-V co-morbidity index was higher in patients with irAEs. Conclusion: These data underscore the needs for tailored irAE diagnostic and management pathways.

KW - Therapy

KW - cancer in the elderly

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85115852942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115852942&partnerID=8YFLogxK

U2 - 10.1080/07357907.2021.1913502

DO - 10.1080/07357907.2021.1913502

M3 - Article

C2 - 33829943

AN - SCOPUS:85115852942

VL - 39

SP - 789

EP - 796

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 10

ER -

Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this